Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$3.82 -2.1%	$3.61	$2.28 ▼ $6.96	$31.58M	0.55	89,187 shs	32,963 shs
KALA KALA BIO	$5.74 -3.9%	$4.51	$2.92 ▼ $11.20	$37.04M	-1.88	50,071 shs	42,843 shs
RNTX Rein Therapeutics	$1.42 +1.4%	$1.76	$1.33 ▼ $4.40	$31.46M	1.22	36,467 shs	10,360 shs
TRAW Traws Pharma	$1.60 -1.2%	$1.49	$0.97 ▼ $19.44	$8.90M	1.46	453,532 shs	46,560 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	0.00%	+6.41%	-12.59%	+27.33%	-20.25%
KALA KALA BIO	0.00%	-1.88%	+35.38%	+66.38%	-23.06%
RNTX Rein Therapeutics	0.00%	-1.39%	-13.41%	-16.47%	+141,999,900.00%
TRAW Traws Pharma	0.00%	+5.26%	-3.03%	-19.19%	+159,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLNN Clene	2.9827 of 5 stars	3.6	5.0	0.0	0.0	0.0	2.5	0.6
KALA KALA BIO	3.8339 of 5 stars	3.5	2.0	0.0	4.4	1.8	0.8	0.6
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	0.3837 of 5 stars	0.0	5.0	0.0	0.0	0.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLNN Clene	3.17	Buy	$40.00	947.12% Upside
KALA KALA BIO	3.00	Buy	$13.00	126.48% Upside
RNTX Rein Therapeutics	0.00	N/A	N/A	N/A
TRAW Traws Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TRAW, RNTX, CLNN, and KALA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
7/11/2025	KALA KALA BIO	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/30/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/8/2025	CLNN Clene	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $33.00
5/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/23/2025	CLNN Clene	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLNN Clene	$350K	90.23	N/A	N/A	($1.06) per share	-3.60
KALA KALA BIO	$3.89M	9.52	N/A	N/A	$2.02 per share	2.84
RNTX Rein Therapeutics	N/A	N/A	$0.45 per share	3.17	$0.43 per share	N/A
TRAW Traws Pharma	$230K	38.68	N/A	N/A	($8.66) per share	-0.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLNN Clene	-$39.40M	-$4.04	N/A	N/A	N/A	-8,306.00%	N/A	-105.11%	8/6/2025 (Estimated)
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)
RNTX Rein Therapeutics	-$62.88M	-$2.86	N/A	N/A	N/A	N/A	-86.07%	-31.11%	N/A
TRAW Traws Pharma	-$166.52M	-$32.81	N/A	N/A	N/A	-15,245.81%	N/A	-193.21%	8/21/2025 (Estimated)

Latest TRAW, RNTX, CLNN, and KALA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	CLNN Clene	-$0.49	N/A	N/A	N/A	$0.06 million	N/A
8/5/2025	Q2 2025	KALA KALA BIO	-$1.82	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	RNTX Rein Therapeutics	-$0.21	-$0.25	-$0.04	-$0.25	N/A	N/A
5/15/2025	Q1 2025	TRAW Traws Pharma	-$8.04	$2.09	+$10.13	$2.09	$0.06 million	$0.06 million
5/7/2025	Q1 2025	CLNN Clene	-$1.10	-$0.50	+$0.60	-$0.09	$0.07 million	$0.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLNN Clene	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLNN Clene	N/A	1.36	1.36
KALA KALA BIO	3.19	1.99	1.99
RNTX Rein Therapeutics	N/A	1.39	1.39
TRAW Traws Pharma	N/A	1.81	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLNN Clene	23.28%
KALA KALA BIO	24.61%
RNTX Rein Therapeutics	90.89%
TRAW Traws Pharma	7.95%

Insider Ownership

Company	Insider Ownership
CLNN Clene	35.30%
KALA KALA BIO	8.32%
RNTX Rein Therapeutics	5.10%
TRAW Traws Pharma	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLNN Clene	100	8.27 million	5.35 million	Optionable
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable
RNTX Rein Therapeutics	9	22.15 million	21.02 million	N/A
TRAW Traws Pharma	17	5.56 million	4.81 million	Optionable

TRAW, RNTX, CLNN, and KALA Headlines

Recent News About These Companies

TRAW - Traws Pharma Inc Sustainability - Morningstar

July 16, 2025 | morningstar.comM

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

July 8, 2025 | msn.com

Traws Pharma announces chief financial officer transition

July 5, 2025 | uk.investing.com

Traws Pharma, Inc. (TRAW) Income Statement - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Traws Pharma, Inc.: Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

June 30, 2025 | finanznachrichten.de

Traws Pharma Submits Phase 2 Protocols for Tivoxavir Marboxil and Ratutrelvir to HREC and FDA

June 30, 2025 | quiverquant.comQ

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

June 30, 2025 | globenewswire.com

Traws Pharma Announces Promising Clinical Data for Rigosertib in Rare Cancer

June 5, 2025 | msn.com

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

June 3, 2025 | globenewswire.com

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025 | globenewswire.com

Traws Pharma Unveils New Strategic Antiviral Focus

May 19, 2025 | tipranks.com

Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments

May 18, 2025 | msn.com

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025 | globenewswire.com

Traws Pharma Appoints New Chairman Amid Leadership Changes

April 18, 2025 | tipranks.com

The Escalator: HHS, Spectrum Science, Alvotech and more

April 3, 2025 | mmm-online.comM

Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs

April 2, 2025 | msn.com

Traws Pharma reports FY24 EPS ($35.21)

April 1, 2025 | markets.businessinsider.com

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

April 1, 2025 | seekingalpha.com

Traws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business Highlights

March 31, 2025 | finanznachrichten.de

Traws Pharma Reports Full Year 2024 Results and Business Highlights

March 31, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW, RNTX, CLNN, and KALA Company Descriptions

Clene NASDAQ:CLNN

$3.82 -0.08 (-2.05%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.74 -0.07 (-1.96%)

As of 07/18/2025 05:17 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

KALA BIO NASDAQ:KALA

$5.74 -0.23 (-3.85%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.78 +0.04 (+0.78%)

As of 07/18/2025 06:42 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Rein Therapeutics NASDAQ:RNTX

$1.42 +0.02 (+1.43%)

As of 07/18/2025 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Traws Pharma NASDAQ:TRAW

$1.60 -0.02 (-1.23%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.61 +0.01 (+0.56%)

As of 07/18/2025 07:50 PM Eastern

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time